Actively Recruiting
Evaluating Safety, Activity, and Pharmacokinetics of Divarasib Alone or With Other Anti-Cancer Therapies in Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation
Led by Hoffmann-La Roche · Updated on 2026-10-06
320
Participants Needed
71
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, pharmacokinetics, and activity of the drug divarasib alone or combined with other anti-cancer treatments in adults with previously untreated advanced or metastatic non-small cell lung cancer NSCLC that has a KRAS G12C mutation. This phase IbII open-label study involves participants who have not received prior systemic treatment for advanced or metastatic NSCLC and aims to better understand how divarasib works and its side effects. Participants will be assigned to different groups receiving divarasib orally once daily at varying dose levels combined with pembrolizumab given as an intravenous infusion every three weeks. Some groups will also receive platinum-based chemotherapy carboplatin or cisplatin and pemetrexed. The study includes dose finding and dose expansion stages, with some participants randomized to different combination dose levels of divarasib and pembrolizumab. During the study, participants will be monitored for adverse events from baseline until 60 days after the last dose or until starting another anti-cancer therapy, up to about five years. Researchers will assess response rates, duration of response, progression-free survival, symptom side effects through patient questionnaires, and drug levels in plasma or cerebrospinal fluid. Safety and activity will be observed through regular clinical visits, imaging, and laboratory tests throughout the study period.
CONDITIONS
Brief Title
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Research Team
R
Reference Study ID Number: BO44426 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here